TITLE

Does Androgen Deprivation Improve Outcomes for Localized Prostate Cancer?

PUB. DATE
October 2011
SOURCE
Clinical Trials Administrator;Oct2011, Vol. 9 Issue 10, p20
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports a trial conducted by C. U. Jones and colleagues, of radiotherapy for men with localized prostate cancer with short term androgen-deprivation treatment, revealed significant decrease in prostate cancer associated deaths and increased overall survival.
ACCESSION #
65550355

 

Related Articles

  • Does Androgen Deprivation Improve Outcomes for Localized Prostate Cancer? Kuritzky, Louis // Hospital Medicine Alert;Oct2011 Clinical Briefs Supplement, p20 

    The article reports on the study by C. U. Jones and colleagues which found that short-term androgen deprivation enhanced outcomes in localized prostate cancer patients who are undergoing radiotherapy.

  • Primary ADT linked to lower survival in American men. Krader, Cheryl Guttman // Urology Times;Nov2013, Vol. 41 Issue 12, p8 

    The article cites a new research study on the effectiveness of primary androgen deprivation therapy (ADT) for localized prostate cancer. The study found that the therapy has better survival outcomes in a Japanese cohort compared with an American population. The reasons for this difference are...

  • Does Androgen Deprivation Improve Outcomes for Localized Prostate Cancer?  // Critical Care Alert;Oct2011 Clinical Briefs Supplement, p20 

    No abstract available.

  • Does Androgen Deprivation Improve Outcomes for Localized Prostate Cancer?  // Clinical Cardiology Alert;Oct2011 Clinical Briefs, p20 

    The article reports the findings of a study by C. U. Jones and colleagues, which examined the survival benefits of androgen-deprivation treatment in patients with localized prostate cancer.

  • Does Androgen Deprivation Improve Outcomes for Localized Prostate Cancer? Kuritzky, Louis // Clinical Oncology Alert;Oct2011 Supplement, p20 

    No abstract available.

  • Abiraterone acetate increases survival in chemotherapy-naïve metastatic prostate cancer.  // British Journal of Hospital Medicine (17508460);Nov2014, Vol. 75 Issue 11, p610 

    The article highlights the results of a research study on the effectiveness of combining abiraterone acetate and low dose prednisolone in extending the survival of patients with metastatic prostate cancer.

  • Nearly 200,000 non-metastatic PCa patients on ADT. Krader, Cheryl Guttman // Urology Times;Jul2012, Vol. 40 Issue 8, p18 

    The article reports on the results of a study regarding the prevalence of the use of androgen deprivation therapy (ADT) in the U.S. According to the results, almost 190,000 men having non-metastatitc prostate cancer were continuously being treated with ADT. Moreover, the study concluded that ADT...

  • Antiandrogen for PCa shows improvement in survival, QoL. Bankhead, Charles // Urology Times;Sep2012, Vol. 40 Issue 10, p10 

    The article focuses on the therapeutic effect of androgen receptor signaling inhibitor enzalutamide on cancer patient survival and quality of Life (QoL). Data show that using enzalutamide, men with castration-resistant prostate cancer (CRPC) were able to live nearly five months longer. Research...

  • Androgen blockade can be cut from 36 to 18 months. Goodman, Alice // Urology Times;Apr2013, Vol. 41 Issue 4, p6 

    The article reports on the results of a phase III study on patients with prostate cancer. The study showed that patients with high-risk prostate cancer who undergo 18 months of androgen blockade have lived as long as those who have 36 months of treatment. Dr. Abdenour Nabid of Centre Hospitalier...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics